Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468154 | 0.90 | TSHR (0.37) | TSHRALDH1A1NPC1LMNASMN1; SMN2 | |
| SCHEMBL4468158 | 0.90 | TSHR (0.37) | TSHRALDH1A1NPC1LMNASMN1; SMN2 | |
| SCHEMBL3988575 | 0.86 | TSHR (0.38) | TSHRALDH1A1NPC1POLBTP53 | |
| SCHEMBL13939574 | 0.86 | TSHR (0.38) | TSHRALDH1A1NPC1POLBTP53 | |
| SCHEMBL12340534 | 0.86 | TSHR (0.48) | TSHRALDH1A1NPC1LMNAPOLB | |
| SCHEMBL12340729 | 0.86 | GPR139 (0.34) | TSHRALDH1A1NPC1LMNASMN1; SMN2 | |
| SCHEMBL5847419 | 0.85 | TSHR (0.35) | TSHRALDH1A1NPC1LMNASMN1; SMN2 | |
| SCHEMBL4467301 | 0.85 | TSHR (0.38) | TSHRALDH1A1NPC1KMT2APOLB | |
| SCHEMBL5847425 | 0.85 | TSHR (0.36) | TSHRALDH1A1NPC1KMT2APOLB | |
| SCHEMBL4470883 | 0.83 | TSHR (0.35) | TSHRALDH1A1NPC1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | TSHR 4713/4885ALDH1A1 792/4885NPC1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.